Compare DEC & CRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DEC | CRON |
|---|---|---|
| Founded | 2001 | N/A |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.0B |
| IPO Year | 2022 | 2015 |
| Metric | DEC | CRON |
|---|---|---|
| Price | $14.53 | $2.58 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $21.40 | N/A |
| AVG Volume (30 Days) | 610.5K | ★ 1.0M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 7.98% | N/A |
| EPS Growth | ★ 311.06 | N/A |
| EPS | ★ 4.58 | N/A |
| Revenue | ★ $1,829,142,000.00 | $146,587,000.00 |
| Revenue This Year | $18.28 | $32.15 |
| Revenue Next Year | N/A | $10.45 |
| P/E Ratio | $3.18 | ★ N/A |
| Revenue Growth | ★ 141.54 | 24.63 |
| 52 Week Low | $10.08 | $1.60 |
| 52 Week High | $16.86 | $3.43 |
| Indicator | DEC | CRON |
|---|---|---|
| Relative Strength Index (RSI) | 64.34 | 43.41 |
| Support Level | $14.01 | $2.44 |
| Resistance Level | $15.49 | $2.59 |
| Average True Range (ATR) | 0.49 | 0.09 |
| MACD | 0.15 | -0.01 |
| Stochastic Oscillator | 85.20 | 25.00 |
Diversified Energy Co is an independent energy company focused on natural gas and liquids production, transportation, marketing and well retirement, located within the Appalachian and Central regions of the United States. Its principal focus is on enhancing producing wells, not drilling new wells, thereby allowing it to optimise PDP revenues and reduce costs. The company derives revenues from the sale of oil, natural gas and natural gas liquids.
Cronos Group Inc headquartered in Toronto, Canada, cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis primarily to Israel. In the U.S., the company has an option to acquire 5.9% of U.S. multistate operator PharmaCann on a fully diluted basis upon easing of federal prohibition.